Aktieanalys

Inhalation Sciences Q3: Continuing its journey towards profitability - Redeye

Redeye Publicerad: 23 Nov 2023 07:16

Redeye provides an update in relation to ISAB’s Q3 2023 report. Revenues during the quarter amounted to SEK3.4m (SEK1.8m), and EBIT came in at SEK-1.0m (SEK-3.5m). Revenues came in lower than anticipated; however, ISAB continues to keep its costs low. Moreover, we note that the order flow after the reporting period has been solid, arguing the coming quarters will be interesting for the company. We make some adjustments to our OPEX estimates and increase our WACC. However, the changes do not render in an updated fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/962250/inhalation-sciences-q3-continuing-its-journey-towards-profitability?utm_source=finwire&utm_medium=RSS

Nyheter om Inhalation Sciences

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!